Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27311346 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MAPTHPGDHSD17B10MAPK1 | |
| Hydrochloric Acid SCHEMBL17824412 | 0.98 | ALDH1A1 (0.54) | ALDH1A1MAPTHPGDHSD17B10MAPK1 | |
| Trifluoroacetic Acid SCHEMBL28276760 | 0.91 | MAPT (0.49) | ALDH1A1MAPTHPGDHSD17B10KMT2A | |
| Hydrochloric Acid SCHEMBL6738405 | 0.90 | ALDH1A1 (0.50) | ALDH1A1MAPTHPGDHSD17B10MGLL | |
| SCHEMBL25046474 | 0.88 | ALDH1A1 (0.49) | ALDH1A1MAPTHPGDHSD17B10KMT2A | |
| SCHEMBL22692566 | 0.84 | ALDH1A1 (0.58) | ALDH1A1MAPTHPGDHSD17B10MAPK1 | |
| SCHEMBL4415396 | 0.83 | OPRK1 (0.51) | ALDH1A1MAPTHPGDHSD17B10MAPK1 | |
| SCHEMBL4415399 | 0.83 | OPRK1 (0.51) | ALDH1A1MAPTHPGDHSD17B10MAPK1 | |
| SCHEMBL8031605 | 0.83 | ELANE (0.53) | ALDH1A1MAPTHSD17B10MAPK1KMT2A | |
| SCHEMBL655368 | 0.83 | ELANE (0.53) | ALDH1A1MAPTHSD17B10MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213645-A1 | PHARMACEUTICAL COMPOSITION FOR MODULATING IMMUNE RESPONSE | L-Base Co., Ltd. (KR) | 2025-07-03 | — | — | US | disclosed |
| EP-3994122-B1 | N-FORMYLHYDROXYLAMINES AS NEPRILYSIN (NEP) INHIBITORS, IN PARTICULAR AS MIXED INHIBITORS OF AMINOPEPTIDASE N (APN) AND NEPRILYSIN (NEP) | KOS THERAPEUTICS INC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240207355-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | L-Base Co., Ltd. (KR) | 2024-06-27 | — | — | US | disclosed |
| EP-4062974-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | L BASE CO LTD (KR) | 2024-05-08 | — | — | EP | disclosed |
| EP-4335452-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | L-Base Co., Ltd. (KR) | 2024-03-13 | — | — | EP | disclosed |
| CN-117083074-A | Pharmaceutical composition for enhancing anticancer effect of anticancer drug | L 基础有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20230159587-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | L-Base Co., Ltd. (KR) | 2023-05-25 | — | — | US | disclosed |
| WO-2023043261-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | 주식회사 엘베이스 | 2023-03-23 | — | — | WO | disclosed |
| WO-2023043269-A1 | PHARMACEUTICAL COMPOSITION FOR MODULATING IMMUNE RESPONSE | 주식회사 엘베이스 | 2023-03-23 | — | — | WO | disclosed |
| WO-2023043271-A1 | METHOD FOR CHARACTERIZING RESPONDER TO CAGE INHIBITOR FOR CANCER THERAPY | 주식회사 엘베이스 | 2023-03-23 | — | — | WO | disclosed |
| EP-3342599-B1 | HEAT-SENSITIVE RECORDING MATERIAL | SANKO CO LTD (JP) | 2021-06-16 | — | — | EP | disclosed |
| US-10800809-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | LAURUS LABS LIMITED (IN) | 2020-10-13 | — | — | US | disclosed |
| US-20190284231-A1 | PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LIMITED (IN) | 2019-09-19 | — | — | US | disclosed |
| US-10364269-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | LAURUS LABS LIMITED (IN) | 2019-07-30 | — | — | US | disclosed |
| US-20190085026-A1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Laurus Labs Ltd. (IN) | 2019-03-21 | — | — | US | disclosed |
| US-10086634-B2 | Heat-sensitive recording material | SANKO CO., LTD. (JP) | 2018-10-02 | — | — | US | disclosed |
| US-20180194151-A1 | HEAT-SENSITIVE RECORDING MATERIAL | SANKO CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3342599-A1 | HEAT-SENSITIVE RECORDING MATERIAL | Sanko Co., Ltd. (JP) | 2018-07-04 | — | — | EP | disclosed |
| EP-3297678-A1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Laurus Labs Private Limited (IN) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016185450-A1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194151-A1 | HEAT-SENSITIVE RECORDING MATERIAL | ASIC1, SCN1A, NPR1 | ALDH1A1 1820/4885MAPT 4261/4885HPGD 2285/4885 |
| US-20230159587-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | VIP, QPCT, TPT1 | ALDH1A1 4754/4885MAPT 633/4885HPGD 1710/4885 |
| US-20190085026-A1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | PRCP, SF3B5, GBA1 | ALDH1A1 3950/4885MAPT 2129/4885HPGD 4740/4885 |
| US-10364269-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | SF3B5, PRCP, GBA1 | ALDH1A1 3880/4885MAPT 1281/4885HPGD 4735/4885 |
| US-20250213645-A1 | PHARMACEUTICAL COMPOSITION FOR MODULATING IMMUNE RESPONSE | ATG7, CCL11, ATG13 | ALDH1A1 4701/4885MAPT 415/4885HPGD 2155/4885 |
| US-10086634-B2 | Heat-sensitive recording material | ASIC1, SCN1A, NPR1 | ALDH1A1 1666/4885MAPT 3657/4885HPGD 2311/4885 |
| US-10800809-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | SF3B5, PRCP, GBA1 | ALDH1A1 3880/4885MAPT 1281/4885HPGD 4735/4885 |
| US-20240207355-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG | ALPG, SLC11A2, SGTA | ALDH1A1 4761/4885MAPT 1532/4885HPGD 3278/4885 |
| US-20190284231-A1 | PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SF3B5, PRCP, GBA1 | ALDH1A1 3880/4885MAPT 1281/4885HPGD 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.